Treatment of rapidly progressive systemic sclerosis: current and futures perspectives

Bibliography

• Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–567.
   PubMed Web of Science ®Google Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.
   PubMed Web of Science ®Google Scholar
• Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509–537.
   PubMed Web of Science ®Google Scholar
• Pattanaik D, Brown M, Postlethwaite BC, et al. Pathogenesis of systemic sclerosis. Front Immunol. 2015;6:272.
   PubMed Web of Science ®Google Scholar
• Stern EP, Denton CP. The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am. 2015;41:367–382.
   PubMed Web of Science ®Google Scholar
• Mendoza FA, Keyes-Elstein LL, Jimenez SA. Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res. 2012;64:945–954.
   Web of Science ®Google Scholar
• Pope JE, Khanna D, Johnson SR, et al. Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. Arthritis Care Res. 2012;64:955–959.
   Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–1755.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–2747.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205.
   PubMed Web of Science ®Google Scholar
• Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31:196–203.
   PubMed Web of Science ®Google Scholar
• Assassi S, del Junco D, Sutter K, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum. 2009;61:1403–1411.
   PubMed Web of Science ®Google Scholar
• Domsic RT, Rodriguez-Reyna T, Lucas M, et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70:104–109.
   PubMed Web of Science ®Google Scholar
• Bryan C, Knight C, Black CM, et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 1999;42:2660–2665.
   PubMed Web of Science ®Google Scholar
• Muangchan C, Harding S, Khimdas S, et al. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken). 2012;64:1405–1414.
   PubMed Web of Science ®Google Scholar
• Shulman LE, Kurban AK, Harvey A. Tendon friction rubs in progressive system sclerosis (scleroderma). Trans Assoc Am Physicians. 1961;74:378–388.
   PubMedGoogle Scholar
• Steen VD, Medsger TA. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum. 1997;40:1146–1151.
   PubMed Web of Science ®Google Scholar
• Khanna PP, Furst DE, Clements PJ, et al. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford). 2010;49:955–959.
   PubMed Web of Science ®Google Scholar
• Doré A, Lucas M, Ivanco D, et al. Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken). 2013;65:1385–1389.
   PubMed Web of Science ®Google Scholar
• Czirják L, Kumánovics G, Varjú C, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67:59–63.
   PubMed Web of Science ®Google Scholar
• Ostojić P, Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol. 2006;25:453–457.
   PubMed Web of Science ®Google Scholar
• Mendoza F, Derk CT. Systemic sclerosis mortality in the United States: 1999–2002 implications for patient care. J Clin Rheumatol. 2007;13:187–192.
   PubMed Web of Science ®Google Scholar
• Joven BE, Almodovar R, Carmona L, et al. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum. 2010;39:285–293.
   PubMed Web of Science ®Google Scholar
• Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol. 1998;37:750–755.
   PubMedGoogle Scholar
• Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246–2255.
   PubMed Web of Science ®Google Scholar
• Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24:165–170.
   PubMed Web of Science ®Google Scholar
• Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29:315–333.
   PubMed Web of Science ®Google Scholar
• Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352–357.
   PubMed Web of Science ®Google Scholar
• Bose N, Chiesa-Vottero A, Chatterjee S. Scleroderma renal crisis. Semin Arthritis Rheum. 2015;44:687–694.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Mouthon L. Scleroderma renal crisis. Rheum Dis Clin North Am. 2015;41:475–488.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007;66:940–944.
   PubMed Web of Science ®Google Scholar
• Ngian G, Sahhar J, Proudman SM, et al. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheumatic Dis. 2012;71:1980–1983.
   PubMed Web of Science ®Google Scholar
• Man A, Zhu Y, Zhang Y, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72:1188–1193.
   PubMed Web of Science ®Google Scholar
• Parks JL, Taylor MH, Parks LP, et al. Systemic sclerosis and the heart. Rheum Dis Clin North Am. 2014;40:87–102.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Charoenpong P, Ratanasrimetha P, et al. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33:1099–1104.
   PubMed Web of Science ®Google Scholar
• Rosenbloom J, Mendoza FA, Jimenez SA. Strategies for anti-fibrotic therapies. Biochim Biophys Acta. 2013;1832:1088–1103.
   PubMed Web of Science ®Google Scholar
• McMahan ZH, Wigley FM. Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs. 2014;23:183–198.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Furst DE. Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches. Rheum Dis Clin North Am. 2015;41:399–417.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Daoussis D, Garyfallos A, et al. Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis. Curr Med Chem. 2015;22:1943–1955.
   PubMed Web of Science ®Google Scholar
• Broen JC, Radstake TR, Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol. 2014;10:671–681.
   PubMed Web of Science ®Google Scholar
• Salazar G, Mayes MD. Genetics, epigenetics, and genomics of systemic sclerosis. Rheum Dis Clin Am. 2015;41:345–366.
   PubMed Web of Science ®Google Scholar
• Bossini-Castillo L, López-Isac E, Mayes MD, et al. Genetics of systemic sclerosis. Semin Immunopathol. 2015;37:443–451.
   PubMed Web of Science ®Google Scholar
• Feghali-Bostwick C, Medsger TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48:1956–1963.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001;44:1359–1362.
   PubMed Web of Science ®Google Scholar
• Frech T, Khanna D, Markewitz B, et al. Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. Arthritis Rheum. 2010;62:2109–2116.
   PubMed Web of Science ®Google Scholar
• Luo Y, Wang Y, Wang Q, et al. Systemic sclerosis: genetics and epigenetics. Autoimmunity. 2013;41:161–167.
   Web of Science ®Google Scholar
• Martin JE, Bossini-Castillo L, Martin J. Unraveling the genetic component of systemic sclerosis. Hum Genet. 2012;131:1023–1027.
   PubMed Web of Science ®Google Scholar
• Bossini-Castillo L, López-Isac E, Martin J. Immunogenetics of systemic sclerosis: defining heritablilty, functional variants and shared-autoimmunity pathways. J Autoimm. 2015 Jul 23. Pii: S0896-8411(15)30008-1 DOI:10.1016/j.jaut.2015.07.005. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975;4:351–368.
   PubMedGoogle Scholar
• Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65:1953–1962.
   PubMed Web of Science ®Google Scholar
• Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol. 2015;37:489–500.
   PubMed Web of Science ®Google Scholar
• Altorok N, Wang Y, Kahaleh B. Endothelial dysfunction in systemic sclerosis. Curr Opin Rheumatol. 2014;26:615–620.
   PubMed Web of Science ®Google Scholar
• Duffield JS, Lupher M, Thannickal VJ, et al. Host responses in tissue repair and fibrosis. Annu Rev Pathol. 2013;8:241–276.
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170:1807–1816.
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180:1340–1355.
   PubMed Web of Science ®Google Scholar
• Kramann R, DiRocco DP, Humphreys BD. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol. 2013;231:273–289.
   PubMed Web of Science ®Google Scholar
• Jimenez SA. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol. 2013;2013:835948. DOI:10.1155/2013/835948.
   PubMedGoogle Scholar
• Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2012;14:694–698.
   Web of Science ®Google Scholar
• Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infections. Autoimmune Rev. 2008;8:36–40.
   PubMed Web of Science ®Google Scholar
• Radić M, Martinivić Kaliterna D, Radić J. Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis. Neth J Med. 2010;68:348–353.
   PubMed Web of Science ®Google Scholar
• Moroncini G, Mori S, Tonnini C, et al. Role of viral infections in the etipathogenesis of systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):3–7.
   PubMedGoogle Scholar
• Fattal I, Shental N, Molad Y, et al. Epstein–Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative for anti-DNA. Immunology. 2014;141:276–285.
   PubMed Web of Science ®Google Scholar
• Boin F, de Fanis U, Bartlett SJ, et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 2008;58:1165–1174.
   PubMed Web of Science ®Google Scholar
• Gu YS, Kong J, Cheema GS, et al. The immunobiology of systemc sclerosis. Semin Arthritis Rheum. 2008;38:132–160.
   PubMed Web of Science ®Google Scholar
• O’Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford, England). 2012;51:1540–1549.
   PubMed Web of Science ®Google Scholar
• Fullard N, O’Reilly S. Role of innate immune system in systemic sclerosis. Semin Immunopathol. 2015;37:511–517.
   PubMed Web of Science ®Google Scholar
• Chizzolini C, Boin F. The role of the acquired immune response in systemic sclerosis. Semin Immunopathol. 2015;37:543–557.
   PubMed Web of Science ®Google Scholar
• Raja J, Denton CP. Cytokines in the immunopathology of systemic sclerosis. Semin Immunopathol. 2015;37:543–557.
   PubMed Web of Science ®Google Scholar
• Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5:80–93.
   PubMed Web of Science ®Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35–42.
   PubMed Web of Science ®Google Scholar
• Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340–354.
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Castro SV, Piera-Velazquez S. Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. Curr Rheumatol Rev. 2010;6:283–294.
   PubMedGoogle Scholar
• Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther. 2007;9(Suppl 2):S4.
   PubMed Web of Science ®Google Scholar
• Wei J, Bhattacharyya S, Tourtellotte WG, et al. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev. 2011;10:267–275.
   PubMed Web of Science ®Google Scholar
• Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013;15:215.
   PubMed Web of Science ®Google Scholar
• Mack M, Yanagita M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int. 2015;87:297–307.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179:1074–1080.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Jimenez SA. Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair. 2012;5:S7.
   PubMedGoogle Scholar
• Giordano M. The CREST acronym and some related problems. Arthritis Rheum. 1985;28:359.
   PubMed Web of Science ®Google Scholar
• Rodnan GP, Fennell RH. Progressive systemic sclerosis sine scleroderma. JAMA. 1962;180:665–670.
   PubMed Web of Science ®Google Scholar
• Lally EV, Jimenez SA, Kaplan SR. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum. 1988;18:1–13.
   PubMed Web of Science ®Google Scholar
• Clemson BS, Miller WR, Luck JC, et al. Acute myocarditis in fulminant systemic sclerosis. Chest. 1992;101:872–874.
   PubMed Web of Science ®Google Scholar
• Marasovic-Krstulovic D, Jurisic Z, Perkovic D, et al. Fulminant diffuse systemic sclerosis following aortic valve replacement. Med Hypotheses. 2014;82:792–794.
   PubMed Web of Science ®Google Scholar
• Scussel-Lonzetti L, Joyal F, Raynauld J, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine. 2002;81:154–167.
   PubMed Web of Science ®Google Scholar
• Clements PJ, Lachenbruch PA, Ng SC, et al. Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1990;33:1256–1263.
   PubMed Web of Science ®Google Scholar
• Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–1285.
   PubMed Web of Science ®Google Scholar
• Derk C, Huaman G, Littlejohn J, et al. Predictors of early mortality in systemic sclerosis: a case-control study comparing early versus late mortality in systemic sclerosis. Rheumatol Int. 2012;32:3841–3844.
   PubMed Web of Science ®Google Scholar
• Maurer B, Graf N, Michel BA, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2015;74:1124–1131.
   PubMed Web of Science ®Google Scholar
• Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford). 2009;48:1595–1599.
   PubMed Web of Science ®Google Scholar
• Mendoza FA, Nagle SJ, Lee JB, et al. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012;39:1241–1247.
   PubMed Web of Science ®Google Scholar
• Silver RM, Warrich JH, Kinsella MB. Cyclophosphamide and low dose prednisone therapy in patients with systemic sclerosis (Scleroderma) with interstitial lung disease. J Rheum. 1993;20:838–844.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2666.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol. 2002;29:731–736.
   PubMed Web of Science ®Google Scholar
• Domiciano DS, Bonfá E, Borges CTL, et al. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol. 2011;30:223–229.
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford). 2007;46:442–445.
   PubMed Web of Science ®Google Scholar
• Le EN, Wigley FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011;70:1104–1107.
   PubMed Web of Science ®Google Scholar
• Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60:1102–1111.
   PubMed Web of Science ®Google Scholar
• Postlethwaite AE, Wong WK, Clements P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008;58:1810–1822.
   PubMed Web of Science ®Google Scholar
• Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133:455–460.
   PubMed Web of Science ®Google Scholar
• Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol. 2011;30:1393–1398.
   PubMed Web of Science ®Google Scholar
• Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis: a systematic review. PLoS One. 2015;10:e012425. DOI:10.1371/journal.pone.0124205. eCollection 2015.
   Google Scholar
• Panopoulos ST, Bournia VK, Trakada G, et al. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung. 2013;191:483–489.
   PubMed Web of Science ®Google Scholar
• Pope J, Harding S, Khimdas S, et al. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol. 2012;39:524–531.
   PubMed Web of Science ®Google Scholar
• van den Hoogen FH, Boerbooms AM, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35:364–372.
   PubMedGoogle Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44:1351–1358.
   PubMed Web of Science ®Google Scholar
• Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60:578–583.
   PubMed Web of Science ®Google Scholar
• Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69:193–197.
   PubMed Web of Science ®Google Scholar
• Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12:R54.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49:271–280.
   PubMed Web of Science ®Google Scholar
• McQueen FM, Solanki K. Rituximab in diffuse cutanueous systemic sclerosis: should we be using it today? Rheumatology (Oxford). 2015;54:757–767.
   PubMed Web of Science ®Google Scholar
• Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188–1194.
   PubMed Web of Science ®Google Scholar
• Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015. DOI:10.1016/j.autrev.2015.07.008.
   Web of Science ®Google Scholar
• Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol. 2015;42:236–242.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr, Rodnan GPD. Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982;97:652–659.
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol. 1991;18:1496–1503.
   PubMed Web of Science ®Google Scholar
• Medsger TA Jr, Lucas M, Wildy KS, et al. D-Penicillamine in systemic sclerosis? Yes! Scand J Rheumatol. 2001;30:192–194.
   PubMed Web of Science ®Google Scholar
• Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014;124:1622–1635.
   PubMed Web of Science ®Google Scholar
• Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110:1388–1396.
   PubMed Web of Science ®Google Scholar
• Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR registry. Ann Rheum Dis. 2004;63:974–981.
   PubMed Web of Science ®Google Scholar
• van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490–2498.
   PubMed Web of Science ®Google Scholar
• van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis. 2005;64:1515.
   PubMed Web of Science ®Google Scholar
• Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet. 2011;378:498–506.
   PubMed Web of Science ®Google Scholar
• Tyndall A, Furst DE. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol. 2007;19:604–610.
   PubMed Web of Science ®Google Scholar
• Van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatol (Oxford). 2015. pii: kev117. [Epub ahead of print]
   Web of Science ®Google Scholar
• Asano T. Future treatments in systemic sclerosis. J Dermatol. 2010;37:54–70.
   PubMed Web of Science ®Google Scholar
• Rice LM, Padilla CM, McLaughlin SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015;125:2795–2807.
   PubMed Web of Science ®Google Scholar
• Ikawa Y, Ng PS, Endo K, et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol. 2008;216:680–687.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Takihara T, Chambers RA, et al. A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med. 2012;4:136ra71.
   PubMed Web of Science ®Google Scholar
• Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2008;20:713–719.
   PubMed Web of Science ®Google Scholar
• Meyer C, Liu Y, Dooley S. Caveolin and TGF-β entanglements. J Cell Physiol. 2013;228:2097–2102.
   PubMed Web of Science ®Google Scholar
• Jiang F, Liu GS, Dusting GJ, et al. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox Biol. 2014;1:267–272.
   Google Scholar
• Piera-Velazquez S, Makul A, Jimenez SA. Increased expression of NADPH oxidase 4 (NOX4) in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β. Arthritis Rheumatol. 2015 Jun 19. DOI:10.1002/art.39242. [Epub ahead of print]
   PubMedGoogle Scholar
• Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford). 2014 Jul 26. Pii: keu285. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Wei J, Ghosh AK, Sargent JL, et al. PPARδ downregulation by TGF-β in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PloS One. 2010;5(11):e13778. DOI:10.01371/journal.pone.0013778.
   PubMed Web of Science ®Google Scholar
• Derk CT, Jimenez SA. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev. 2006;5:25–32.
   PubMed Web of Science ®Google Scholar
• Timár O, Szekanecz Z, Kerekes G, et al. Rosuvastin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis-a prospective case-series study. Arthritis Res Ther. 2013;15:R105.
   PubMed Web of Science ®Google Scholar
• Rubén EC, Manuel VR, Agustin OR, et al. Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma. J Dermatol. 2010;37:323–329.
   PubMed Web of Science ®Google Scholar
• Bujor AM, Haines P, Padilla C, et al. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. Int J Mol Med. 2012;30:1473–1480.
   PubMed Web of Science ®Google Scholar
• Bogatkevich GS, Ludwika-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects in lung fibroblasts. Arthritis Rheum. 2009;60:3455–3464.
   PubMed Web of Science ®Google Scholar
• Mihara M, Moriya Y, Ohsugi Y. IL-6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts. Int J Immunopharmacol. 1996;18:89–94.
   PubMed Web of Science ®Google Scholar
• Takemura H, Suzuki H, Fujisawa H, et al. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol. 1998;25:1534–1539.
   PubMed Web of Science ®Google Scholar
• Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford, England). 2010;49:2408–2412.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72:1217–1220.
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Juhreis A, et al. Safety and efficiency of subcutaneous tocilizumab in adults with systemic sclerosis: week 48 data from the fascinate trial. Ann Rheum. 2015. DOI:10.1136/annrheumdis-2015-eular.2281.
   Google Scholar
• Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60:219–224.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70:1003–1009.
   PubMed Web of Science ®Google Scholar
• Gordon J, Udeh U, Doobay K, et al. Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clinical Exp Rheumatol. 2014;32:S–189–93.
   PubMed Web of Science ®Google Scholar
• Khanna D, Sagger R, Mayes MD, et al. A one year phase I/II, open label pilot trial of imanitib mesylate in the treatment of systemic sclerosis associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540–3546.
   PubMed Web of Science ®Google Scholar
• Gordon JK, Martyanov V, Magro C, et al. Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label pilot clinical trial. Arthritis Res Ther. 2015;17:213.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Swaney JS, Chapman C, Correa LD, et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011;336:693–700.
   PubMed Web of Science ®Google Scholar
• Yung YC, Stoddard NC, Mirendil H, et al. Lysophosphatidic Acid signaling in the nervous system. Neuron. 2015;85:669–682.
   PubMed Web of Science ®Google Scholar
• Swaney JS, Chapman C, Correa LD, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010;160:1699–1713.
   PubMed Web of Science ®Google Scholar
• Pattanaik D, Postlethwaite AE. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov Med. 2010;10:161–167.
   PubMed Web of Science ®Google Scholar
• Dees C, Beyer C, Distler A, et al. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis. 2015;74:1621–1625.
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Aaløkken TM, Lund MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol. 2015;67:2205–2212.
   PubMed Web of Science ®Google Scholar
• Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of D-Penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol. 2008;158:1063–1068.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Rigante D, Vitale A, et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res. 2015;61:326–337.
   PubMed Web of Science ®Google Scholar